glp-1 agonists reduce inflammation drugs calm beyond diabetes and weight loss Central glucagon-like peptide 1 receptor

These trials aimed to explore Ozempics potential for improving glycemic control, but it turns out Ozempic had a surprise up its sleevea hidden talent for shedding pounds

Pursuant to 7 CFR 15.3, the University of Arkansas Division of Agriculture offers all its Extension and Research programs and services (including employment) without regard to race, color, sex, national origin, religion, age, disability, marital or veteran status, genetic information, sexual preference, pregnancy or any other legally protected status, and is an equal opportunity institution.

Anyways, teach us, Carley

Clinical Trial Results SURMOUNT-1 trial: Average weight loss of ~20% of total body weight

Patients with these conditions who also have elevated inflammatory markers may experience additional anti-inflammatory benefits, but use solely for inflammation outside established indications is not recommended